Put Option on ACAD 9/9/19
Telah dikemas kini
Bought 
ACAD $20 strike puts with expiration on 1/15/21.
I am calling this a short squeeze. Research published today shows Nuplazid as a promising drug for Parkinsons induced Psychosis. Looking into the research paper, they used a "one sided" P-Value test, which negates the reverse end of the gausian curve. I think they are doctoring the study after mortality rates increased from last trial. Drug still comes with this warning label.
P-Value very significant, but I think it is suspicious.
WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS
Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death.
NUPLAZID is not approved for the treatment of patients with dementia-related psychosis unrelated to the hallucinations and delusions associated with Parkinson’s disease psychosis.
Looking to hold for a week to a month, once the price breaks down. I view this as non news and a short squeeze.
Article doesn't even mention which carriers will reimburse the drug and etc.
ACAD $20 strike puts with expiration on 1/15/21.I am calling this a short squeeze. Research published today shows Nuplazid as a promising drug for Parkinsons induced Psychosis. Looking into the research paper, they used a "one sided" P-Value test, which negates the reverse end of the gausian curve. I think they are doctoring the study after mortality rates increased from last trial. Drug still comes with this warning label.
P-Value very significant, but I think it is suspicious.
WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS
Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death.
NUPLAZID is not approved for the treatment of patients with dementia-related psychosis unrelated to the hallucinations and delusions associated with Parkinson’s disease psychosis.
Looking to hold for a week to a month, once the price breaks down. I view this as non news and a short squeeze.
Article doesn't even mention which carriers will reimburse the drug and etc.
Nota
Cost $1.90 As of 9/9/19, looking for 20% potential profit.
Penafian
Maklumat dan penerbitan adalah tidak dimaksudkan untuk menjadi, dan tidak membentuk, nasihat untuk kewangan, pelaburan, perdagangan dan jenis-jenis lain atau cadangan yang dibekalkan atau disahkan oleh TradingView. Baca dengan lebih lanjut di Terma Penggunaan.